Joseph S. McCracken

Filings by Joseph S. McCracken span 3 companies, the busiest being Savara Inc, Lumos Pharma, Inc. and Nexvet Biopharma plc. Between 31 December 2015 and 16 February 2026, the trades on record add up to 12 filings.

On the market, this insider has only ever bought: 5 purchases, €169k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 4 share grants and 2 option exercises.

The median purchase comes to €27k. Clusters matter here: 3 out of 5 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 17 February 2026, reports an option exercise of €2,680 in Savara Inc. The most recent open-market purchase was published on 2 June 2025, 503 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.